Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

Video

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Though significant response rates have been demonstrated with CD19-targeting CAR T-cells, investigation into other possible B-cell antigen targets are ongoing, says Park. CD22 is of particular interest, though responses do not appear as durable as those seen with CD19-targeting antigens.

Additionally, dual-targeting CAR T-cell therapy may increase response rates in this field. At the 2019 ASH Annual Meeting, an update from a phase I dose-climbing study (ChiCTR1800018143) showed objective response rates of over 90% was shown with CAR T-cells targeting both CD38 and BCMA in patients with extramedullary multiple myeloma.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
© 2024 MJH Life Sciences

All rights reserved.